Literature DB >> 23658441

Protection by immunoglobulin dual-affinity retargeting antibodies against dengue virus.

James D Brien1, Soila Sukupolvi-Petty, Katherine L Williams, Chia-Ying Kao Lam, Michael A Schmid, Syd Johnson, Eva Harris, Michael S Diamond.   

Abstract

Dengue viruses are the most common arthropod-transmitted viral infection, with an estimated 390 million human infections annually and ∼3.6 billion people at risk. Currently, there are no approved vaccines or therapeutics available to control the global dengue virus disease burden. In this study, we demonstrate the binding, neutralizing activity, and therapeutic capacity of a novel bispecific dual-affinity retargeting molecule (DART) that limits infection of all four serotypes of dengue virus.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23658441      PMCID： PMC3700316          DOI： 10.1128/JVI.00327-13

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  31 in total

1.  T cell responses to an HLA-B*07-restricted epitope on the dengue NS3 protein correlate with disease severity.

Authors:  Iva Zivna; Sharone Green; David W Vaughn; Siripen Kalayanarooj; Henry A F Stephens; Dasnayanee Chandanayingyong; Ananda Nisalak; Francis A Ennis; Alan L Rothman
Journal:  J Immunol       Date:  2002-06-01       Impact factor: 5.422

2.  Use of recombinant fusion proteins and monoclonal antibodies to define linear and discontinuous antigenic sites on the dengue virus envelope glycoprotein.

Authors:  F Megret; J P Hugnot; A Falconar; M K Gentry; D M Morens; J M Murray; J J Schlesinger; P J Wright; P Young; M H Van Regenmortel
Journal:  Virology       Date:  1992-04       Impact factor: 3.616

3.  Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants.

Authors:  S C Kliks; S Nimmanitya; A Nisalak; D S Burke
Journal:  Am J Trop Med Hyg       Date:  1988-03       Impact factor: 2.345

4.  Mapping of a dengue virus neutralizing epitope critical for the infectivity of all serotypes: insight into the neutralization mechanism.

Authors:  Philippe Thullier; Caroline Demangel; Hugues Bedouelle; Françoise Mégret; Alain Jouan; Vincent Deubel; Jean-Claude Mazié; Pierre Lafaye
Journal:  J Gen Virol       Date:  2001-08       Impact factor: 3.891

5.  Genotype-specific neutralization and protection by antibodies against dengue virus type 3.

Authors:  James D Brien; S Kyle Austin; Soila Sukupolvi-Petty; Katie M O'Brien; Syd Johnson; Daved H Fremont; Michael S Diamond
Journal:  J Virol       Date:  2010-08-11       Impact factor: 5.103

6.  A ligand-binding pocket in the dengue virus envelope glycoprotein.

Authors:  Yorgo Modis; Steven Ogata; David Clements; Stephen C Harrison
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-20       Impact factor: 11.205

7.  T cell responses in dengue hemorrhagic fever: are cross-reactive T cells suboptimal?

Authors:  Juthathip Mongkolsapaya; Thaneeya Duangchinda; Wanwisa Dejnirattisai; Sirijit Vasanawathana; Panisadee Avirutnan; Aroonroong Jairungsri; Nuanpan Khemnu; Nattaya Tangthawornchaikul; Pojchong Chotiyarnwong; Kanokwan Sae-Jang; Michael Koch; Yvonne Jones; Andrew McMichael; Xiaoning Xu; Prida Malasit; Gavin Screaton
Journal:  J Immunol       Date:  2006-03-15       Impact factor: 5.422

8.  Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever.

Authors:  Juthathip Mongkolsapaya; Wanwisa Dejnirattisai; Xiao-ning Xu; Sirijitt Vasanawathana; Nattaya Tangthawornchaikul; Aroonrung Chairunsri; Siraporn Sawasdivorn; Thaneeya Duangchinda; Tao Dong; Sarah Rowland-Jones; Pa-thai Yenchitsomanus; Andrew McMichael; Prida Malasit; Gavin Screaton
Journal:  Nat Med       Date:  2003-07       Impact factor: 53.440

9.  In-depth analysis of the antibody response of individuals exposed to primary dengue virus infection.

Authors:  Ruklanthi de Alwis; Martina Beltramello; William B Messer; Soila Sukupolvi-Petty; Wahala M P B Wahala; Annette Kraus; Nicholas P Olivarez; Quang Pham; James D Brien; James Brian; Wen-Yang Tsai; Wei-Kung Wang; Scott Halstead; Srisakul Kliks; Michael S Diamond; Ralph Baric; Antonio Lanzavecchia; Federica Sallusto; Aravinda M de Silva
Journal:  PLoS Negl Trop Dis       Date:  2011-06-21

10.  A recombinant Fab neutralizes dengue virus in vitro.

Authors:  P Thullier; P Lafaye; F Mégret; V Deubel; A Jouan; J C Mazié
Journal:  J Biotechnol       Date:  1999-04-15       Impact factor: 3.307
View more
  8 in total

Review 1.  Bispecific antibodies for viral immunotherapy.

Authors:  Elisabeth K Nyakatura; Alexandra Y Soare; Jonathan R Lai
Journal:  Hum Vaccin Immunother       Date:  2016-10-27       Impact factor: 3.452

2.  DENGUE VIRUS. Cryo-EM structure of an antibody that neutralizes dengue virus type 2 by locking E protein dimers.

Authors:  Guntur Fibriansah; Kristie D Ibarra; Thiam-Seng Ng; Scott A Smith; Joanne L Tan; Xin-Ni Lim; Justin S G Ooi; Victor A Kostyuchenko; Jiaqi Wang; Aravinda M de Silva; Eva Harris; James E Crowe; Shee-Mei Lok
Journal:  Science       Date:  2015-07-03       Impact factor: 47.728

Review 3.  Dendritic cells in dengue virus infection: targets of virus replication and mediators of immunity.

Authors:  Michael A Schmid; Michael S Diamond; Eva Harris
Journal:  Front Immunol       Date:  2014-12-17       Impact factor: 7.561

4.  Bispecific Antibody Affords Complete Post-Exposure Protection of Mice from Both Ebola (Zaire) and Sudan Viruses.

Authors:  Julia C Frei; Elisabeth K Nyakatura; Samantha E Zak; Russell R Bakken; Kartik Chandran; John M Dye; Jonathan R Lai
Journal:  Sci Rep       Date:  2016-01-13       Impact factor: 4.379

5.  Defining New Therapeutics Using a More Immunocompetent Mouse Model of Antibody-Enhanced Dengue Virus Infection.

Authors:  Amelia K Pinto; James D Brien; Chia-Ying Kao Lam; Syd Johnson; Cindy Chiang; John Hiscott; Vanessa V Sarathy; Alan D Barrett; Sujan Shresta; Michael S Diamond
Journal:  mBio       Date:  2015-09-15       Impact factor: 7.867

Review 6.  The making of bispecific antibodies.

Authors:  Ulrich Brinkmann; Roland E Kontermann
Journal:  MAbs       Date:  2017 Feb/Mar       Impact factor: 5.857

7.  Dengue virus specific IgY provides protection following lethal dengue virus challenge and is neutralizing in the absence of inducing antibody dependent enhancement.

Authors:  Ashley L Fink; Katherine L Williams; Eva Harris; Travis D Alvine; Thomas Henderson; James Schiltz; Matthew L Nilles; David S Bradley
Journal:  PLoS Negl Trop Dis       Date:  2017-07-07

8.  The Ability of Zika virus Intravenous Immunoglobulin to Protect From or Enhance Zika Virus Disease.

Authors:  Amelia K Pinto; Mariah Hassert; Xiaobing Han; Douglas Barker; Trevor Carnelley; Emilie Branche; Tara L Steffen; E Taylor Stone; Elizabeth Geerling; Karla M Viramontes; Cory Nykiforuk; Derek Toth; Sujan Shresta; Shantha Kodihalli; James D Brien
Journal:  Front Immunol       Date:  2021-09-06       Impact factor: 7.561
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.